Transcriptomics

Dataset Information

0

A safety screening platform for individualized cardiotoxicity assessment


ABSTRACT: Cardiotoxicity remains a major cause of drug withdrawal, partially due to lacking predictability of animal models. Additionally, risk of cardiotoxicity following treatment of cancer patients is treatment limiting. It is unclear which patients will develop heart failure following therapy. Human pluripotent stem cell (hPSC)-derived cardiomyocytes present an unlimited cell source and may offer individualized solutions to this problem. We developed a platform to predict molecular and functional aspects of cardiotoxicity. Our platform can discriminate between the different cardiotoxic mechanisms of existing and novel anthracyclines Doxorubicin (DOXO), Aclarubicin (ACLA) and Amrubicin (AMR). DOXO and ACLA unlike AMR substantially affected the transcriptome, mitochondrial membrane integrity, contractile force and transcription factor availability. Cardiomyocytes recovered fully within two or three weeks, corresponding to the intermittent clinical treatment regimen. Our system permits the study of hPSC-cardiomyocyte recovery and the effects of accumulated dose after multiple dosing, allowing individualized cardiotoxicity evaluation, which effects millions of cancer patients treated with anthracyclines annually.

ORGANISM(S): Homo sapiens

PROVIDER: GSE232331 | GEO | 2023/10/01

REPOSITORIES: GEO

Dataset's files

Source:
Action DRS
Other
Items per page:
1 - 1 of 1

Similar Datasets

2013-06-04 | E-GEOD-33632 | biostudies-arrayexpress
2013-06-04 | GSE33632 | GEO
2015-11-12 | E-GEOD-64476 | biostudies-arrayexpress
2024-10-30 | GSE246548 | GEO
2021-07-01 | GSE118086 | GEO
2021-07-01 | GSE118085 | GEO
2015-11-12 | GSE64476 | GEO
2021-08-22 | MSV000088010 | MassIVE
2022-10-01 | GSE122143 | GEO
2022-06-28 | GSE206803 | GEO